Parenteral Drugs

PDPL21 Aug 2023

Pharmaceuticals

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Parenteral Drugs

Parenteral Drugs

Pharmaceuticals

PDPL21 Aug 2023

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
02-Sep-2010	D	Parenteral Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 02, 2010, inter alia, has recommended a dividend of Rs. 2.00 per equity share for the year ended March 31, 2010, subject to approval of the shareholders of the Company, at the ensuing Annual General Meeting of the Company.	13-Sep-2010
26-Nov-2009	D	Parenteral Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 26, 2009, inter alia, has recommended a dividend of 15% for the year ended March 31, 2009, subject to approval of the shareholders of the Company, at the ensuing Annual General Meeting of the Company.	23-Dec-2009
04-Sep-2008	D	Parenteral Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 04, 2008, inter alia, has recommended dividend of 15% for the year ended March 31, 2008, subject to the approval of shareholders at the ensuing General Meeting.	24-Sep-2008
04-Sep-2007	D	Parenteral Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 03, 2007, has recommended dividend @ 15% (Rs. 1.50 per share) on 56,00,000 equity shares of Rs 10/- each. In addition Board has also recommended issue of Bonus Shares to the holders of equity shares of the Company in the ratio of 1:1 subject to the approval of members of the Company at the forthcoming annual general meeting. The Company also proposes to issue equity shares on rights basis at such proportion and price to be decided at a later stage about which necessary intimation will be given to the exchange in due course of time.	21-Sep-2007
08-Sep-2010	B	SUB. :- Dividend payment and Bonus issue of Parenteral Drugs (India) Ltd. (Scrip Code: 524689) Trading Members of the Exchange are hereby informed that, Parenteral Drugs (India) Ltd. has fixed the Book Closure for the purpose of Dividend payment and Bonus Issue. The transactions in the equity shares of the company should be on an ex- dividend and ex-bonus basis with effect from the under mentioned date. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE Parenteral Drugs (India) Ltd. (524689) Book Closure 15/09/2010 to 15/09/2010 PURPOSE Dividend payment of Rs. 2.00/- per equity share AND Issue of 1 (ONE) fully paid up Bonus equity share for every 3 (THREE) existing equity shares held. Ex- Dividend and Ex-Bonus basis from Date & Sett. No. 13/09/2010 DR-117/2010-2011 Trading Members of the Exchange are requested to take note of it.	15-Sep-2010	1:3
22-Oct-2007	B	SUB. :- Bonus issue of Parenteral Drugs (India) Ltd. (Scrip Code 524689) Trading Members of the Exchange are hereby informed that, Parenteral Drugs (India) Ltd. has fixed the Record Date for the purpose of Bonus Issue. The transactions in the equity shares of the company should be on an ex-bonus basis with effect from the under mentioned date. COMPANY NAME CODE Parenteral Drugs (India) Ltd. 524689 RECORD DATE 05/11/2007 Cum-Bonus basis up to Date & Sett. No. 01/11/2007 DR-151/2007- 2008 Ex-Bonus basis from Date & Sett. No. 02/11/2007 DR-152/2007-2008 PURPOSE ONE Bonus equity share for every ONE existing equity share held. Trading Members of the Exchange are requested to take note of it.	05-Nov-2007	1:1
04-Aug-2023	BC	This is in continuation to Exchange Notice No. 20230110-15 dated January 10, 2023, wherein the Trading Members were advised that w.r.t to the following company, 15 days after suspension had been effe	22-Aug-2023
04-Aug-2023	BC	Sub: Discontinuation of weekly trading in Securities This is in continuation to the Exchange Circular Ref. No. 0163/2023 (Download Ref. No. NSE/CML/55555) dated February 08, 2023, regarding suspen	22-Aug-2023
08-Feb-2023	BC	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 (erstwhile SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2018/77 dated May 3, 2018) issued by Securities and	13-Mar-2023
08-Feb-2023	BC	Sub: Suspension of trading in securities Pursuant to the provisions of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 ('SOP') with respect to Standard Operating Procedure f	13-Mar-2023
17-Jan-2023	BC	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S	17-Feb-2023

No Rights has been declared by PDPL

Book Closure

Record Date	Split Date	Purpose
22-Aug-2023	-	This is in continuation to Exchange Notice No. 20230110-15 dated January 10, 2023, wherein the Trading Members were advised that w.r.t to the following company, 15 days after suspension had been effe
22-Aug-2023	-	Sub: Discontinuation of weekly trading in Securities This is in continuation to the Exchange Circular Ref. No. 0163/2023 (Download Ref. No. NSE/CML/55555) dated February 08, 2023, regarding suspen
13-Mar-2023	-	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 (erstwhile SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2018/77 dated May 3, 2018) issued by Securities and
13-Mar-2023	-	Sub: Suspension of trading in securities Pursuant to the provisions of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 ('SOP') with respect to Standard Operating Procedure f
17-Feb-2023	-	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Parenteral Drugs (India) Ltd ₹2.90(0.00/0.00%)	2.90	+0.00	8.65	-14.71	0.00	-0.01
Lupin Ltd ₹1,654.75(+7.10/0.43%)	1,654.75	+7.10	75,415.25	133.18	36.60	3.91
Ipca Laboratories Ltd ₹1,337.70(-13.30/-0.98%)	1,337.70	-13.30	33,938.01	88.94	61.57	5.46
J B Chemicals & Pharmaceuticals Ltd ₹1,889.90(+4.30/0.23%)	1,889.90	+4.30	29,330.27	80.31	57.90	10.92
Sanofi India Ltd ₹8,624.25(-53.50/-0.62%)	8,624.25	-53.50	19,861.65	59.17	33.61	19.54
IOL Chemicals & Pharmaceuticals Ltd ₹395.55(+3.25/0.83%)	395.55	+3.25	2,322.10	-0.40	13.44	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Gross Sales	1.77	1.44	2.35	2.93	2.57	2.04
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	1.77	1.44	2.35	2.93	2.57	2.04
Other Operating Income	0.04	0.01	0.01	0.01	0.03	0.01
Other Income	52.21	0.00	0.00	0.00	0.00	0.00
Total Income	54.02	1.45	2.36	2.94	2.60	2.05
Total Expenditure	7.66	4.67	5.62	5.57	-0.82	4.91
PBIDT	46.37	-3.21	-3.26	-2.62	3.42	-2.86
Interest	0.00	36.68	35.47	34.10	32.46	32.09
PBDT	46.36	-39.90	-38.72	-36.72	-29.04	-34.95
Depreciation	27.15	4.33	4.33	4.33	4.32	4.34
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	-4.60	-9.70	-9.44	-9.02	-8.51	-8.31
Reported Profit After Tax	23.81	-34.52	-33.61	-32.04	-24.84	-30.97
Extra-ordinary Items	52.21	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-28.40	-34.52	-33.61	-32.04	-24.84	-30.97

EPS (Unit Curr.)	7.99	-11.58	-11.28	-10.74	-8.33	-10.41
EPS (Adj) (Unit Curr.)	7.99	-11.58	-11.28	-10.74	-8.33	0.00
Calculated EPS (Unit Curr.)	7.99	-11.58	-11.27	-10.74	-8.33	-10.39
Calculated EPS (Adj) (Unit Curr.)	7.99	-11.58	-11.27	-10.74	-8.33	0.00
Calculated EPS (Ann.) (Unit Curr.)	31.95	-46.32	-45.09	-42.98	-33.33	-41.55
Calculated EPS (Adj) (Ann.) (Unit Curr.)	31.95	-46.32	-45.09	-42.98	-33.33	0.00
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	29.82	29.82	29.82	29.82	29.82	29.82
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	2619.77	-222.92	-138.72	-89.42	133.07	-140.20
PBDTM(%)	2619.21	-2770.83	-1647.66	-1253.24	-1129.96	-1713.24
PATM(%)	1345.20	-2397.22	-1430.21	-1093.52	-966.54	-1518.14

Column	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Gross Sales	1.77	1.44	2.35	2.93	2.57	2.04
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	1.77	1.44	2.35	2.93	2.57	2.04
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	52.25	0.01	0.01	0.01	0.03	0.01
Total Income	54.02	1.45	2.36	2.94	2.60	2.05
Total Expenditure	7.66	4.67	5.62	5.57	-0.82	4.91
PBIDT	46.37	-3.21	-3.26	-2.62	3.42	-2.86
Interest	0.00	36.68	35.47	34.10	32.46	32.09
PBDT	46.36	-39.90	-38.72	-36.72	-29.04	-34.95
Depreciation	27.15	4.33	4.33	4.33	4.32	4.34
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	-4.60	-9.70	-9.44	-9.02	-8.51	-8.31
Reported Profit After Tax	23.81	-34.52	-33.61	-32.04	-24.85	-30.97
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	23.81	-34.52	-33.61	-32.04	-24.85	-30.97

Extra-ordinary Items	52.21	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-28.40	-34.52	-33.61	-32.04	-24.85	-30.97

EPS (Unit Curr.)	7.99	-11.58	-11.28	-10.74	-8.33	-10.41
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	29.81	29.82	29.82	29.82	29.82	29.82

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	2619.77	-222.92	-138.72	-89.42	133.07	-140.20
PBDTM(%)	2619.21	-2770.83	-1647.66	-1253.24	-1129.96	-1713.24
PATM(%)	1345.20	-2397.22	-1430.21	-1093.52	-966.93	-1518.14

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
SOURCES OF FUNDS :
Share Capital	106.53	106.53	106.53	106.53	29.82	42.85
Reserves Total	-747.57	-626.00	-511.62	-172.14	-76.03	246.57
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	34.55	34.55	34.55	34.55	34.55	0.00
Total Shareholders Funds	-606.49	-484.92	-370.54	-31.06	-11.66	289.42
Secured Loans	528.39	528.39	528.59	529.33	529.33	499.84
Unsecured Loans	29.52	29.52	32.00	32.59	107.99	88.55
Total Debt	557.91	557.91	560.59	561.92	637.32	588.39
Total Liabilities	-48.58	72.99	190.05	530.86	625.66	877.81
APPLICATION OF FUNDS :
Gross Block	785.40	785.40	785.40	786.37	784.05	784.05
Less : Accumulated Depreciation	463.58	446.26	428.91	169.45	149.92	130.82
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	321.82	339.14	356.49	616.92	634.13	653.23
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	2.58	2.58	2.58	2.58	3.05	138.69
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	1.59	1.26	3.97	1.25	2.42	15.10
Sundry Debtors	0.00	0.00	0.00	0.37	57.36	85.16
Cash and Bank	0.06	0.11	0.45	0.78	0.96	2.29
Loans and Advances	65.70	65.38	62.16	62.35	6.19	6.96
Total Current Assets	67.35	66.74	66.58	64.75	66.93	109.51
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	604.94	467.86	340.58	226.05	127.11	26.49
Provisions	10.31	9.46	8.38	7.25	6.89	5.85
Total Current Liabilities	615.25	477.31	348.95	233.31	134.00	32.34
Net Current Assets	-547.90	-410.57	-282.38	-168.56	-67.07	77.16
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	165.83	133.12	105.35	71.77	48.65	45.21
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	44.11
Net Deferred Tax	165.83	133.12	105.35	71.77	48.65	1.10
Total Assets	-57.68	64.27	182.04	522.71	618.76	870.18
Contingent Liabilities	135.04	135.04	148.35	136.27	135.66	125.30

Column	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
SOURCES OF FUNDS :
Share Capital	106.53	106.53	106.53	155.03	29.82	47.70
Reserves Total	-747.24	-625.67	-511.29	-208.70	-89.71	277.68
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	34.55	34.55	34.55	42.45	42.45	0.00
Total Shareholders Funds	-606.16	-484.59	-370.21	-11.22	-17.44	325.38
Minority Interest	0.12	0.12	0.12	0.28	0.28	0.65
Secured Loans	528.87	528.87	531.55	586.03	592.70	531.61
Unsecured Loans	30.00	30.00	30.00	55.91	179.21	120.49
Total Debt	558.87	558.87	561.55	641.94	771.91	652.10
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.12	0.14	0.15	0.17	0.18	0.00
Total Liabilities	-47.05	74.54	191.61	631.17	754.93	978.13
APPLICATION OF FUNDS :
Gross Block	785.40	785.40	785.40	915.41	913.05	1041.33
Less: Accumulated Depreciation	463.58	446.26	428.91	199.60	174.39	149.51
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	321.82	339.14	356.49	715.81	738.66	891.82
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	2.40	2.40	2.40	0.00	0.52	0.02
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	1.59	1.26	3.97	27.01	45.05	56.27
Sundry Debtors	0.00	0.00	0.00	3.66	62.33	92.42
Cash and Bank	0.06	0.11	0.45	3.55	3.23	4.57
Loans and Advances	66.43	66.10	62.89	64.83	11.09	9.89
Total Current Assets	68.07	67.47	67.31	99.05	121.71	163.15
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	604.94	467.86	340.58	250.84	150.57	75.10
Provisions	10.31	9.46	8.38	8.41	8.25	8.37
Total Current Liabilities	615.25	477.32	348.96	259.25	158.81	83.48
Net Current Assets	-547.18	-409.85	-281.65	-160.20	-37.11	79.67
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	165.83	133.12	105.35	63.91	41.78	48.70
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	53.08
Net Deferred Tax	165.83	133.12	105.35	63.91	41.78	-4.38
Other Assets	10.08	9.72	9.02	11.65	11.08	11.00
Total Assets
Contingent Liabilities	135.04	135.04	148.35	136.27	135.66	125.84

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Cash and Cash Equivalents at Beginning of the year	0.11	0.09	0.01	0.28	0.16
Net Cash from Operating Activities	125.32	112.37	455.79	148.38	120.98
Net Cash Used In Investing Activities	0.06	0.08	0.10	-0.75	-0.23
Net Cash Used In Financing Activities	-125.44	-112.43	-455.79	-147.91	-120.63
Net Inc./Dec In Cash And Cash Equivalents	-0.05	0.01	0.09	-0.28	0.12
Cash And Cash Equivalents At End Of The Year	0.06	0.11	0.09	0.01	0.28

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

73.29%

FII Shareholding

0.00%

DII Shareholding

0.01%

Public Shareholding

26.71%

**Promoter pledged shareholding 73.29%

About Parenteral Drugs (India) Ltd

Parenteral Drugs (India) Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 10.11 crores. It has reported a sales of Rs. 1.77 crores and a net profit of Rs. 23.81 crores for the quarter ended December 2018. The company management includes Manoharlal Gupta, Manoharlal Gupta,Govind Das Garg,Dharam Pal Khanna,Dilip Kumar Sinha,Anil Mittal,Manish Verma,Vinod Kumar Gupta,Deepali Garhewal,Chhaya Gupta (Parenteral Drugs (India) Ltd) among others.

Chairman

Manoharlal Gupta

Registered office

340 Laxmi Plaza Laxmi Indl Est,New Link Road Andheri (West),Mumbai,Maharashtra,400053

FAX :91-022-26333763

Background

Incorporation Year1983

Face Value₹10

Market Lot1

How to buy Parenteral Drugs shares on nse?

To buy Parenteral Drugs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Parenteral Drugs share price today?

The Parenteral Drugs shares price on nse is Rs.2.9 today.

What is the market cap of Parenteral Drugs shares on NSE ?

The company has a market capitalization of Rs.8.65Cr

What is the PE & PB ratio of Parenteral Drugs shares ?

PE is 0 and PB is -0.01

What is the 52 Week High and Low of Parenteral Drugs shares?

Parenteral Drugs stock price high: Rs.3.3 Parenteral Drugs stock price low: Rs.2.7